Replies to post #220391 on Biotech Values

[DewDiligence]

ENTA has disclosed the royalty-rate tiers for the 50% of Mavyret sales attributable to Glecaprevir (ENTA’s HCV protease inhibitor):

https://www.sec.gov/Archives/edgar/data/1177648/000156459018021062/enta-10q_20180630.htm (page 12):

[DewDiligence]

Transcript of ENTA FY3Q18 CC (8/7/18):

https://finance.yahoo.com/news/edited-transcript-enta-earnings-conference-195436339.html

[Jay Luly, CEO]: First…I want to comment on our increasing royalty revenue from AbbVie related to MAVIRET, currently the best-selling HCV drug in the world, as well as today's announcement from Express Scripts that it has excluded MAVIRET from its HCV formulary for 2019.

As a preliminary matter, this announcement only affects the formulary for 2019, has no impact on MAVIRET access in 2018. More importantly, AbbVie has advised us that Express Scripts' sales represent only a small percentage of MAVIRET sales in the U.S. this year… AbbVie does not believe there will be any significant change in market access for MAVIRET in the U.S. in 2019 compared to 2018.